Close
RNS Number : 6880A
Alliance Pharma PLC
25 May 2023
 

For immediate release

25 May 2023

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")


Result of AGM

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, at its Annual General Meeting held earlier today, all the resolutions, as set out in the Notice of Meeting, were duly passed on a poll.

The number of the Group's shares in issue as at the date of the meeting was 540,124,673 ordinary shares of 1p each.

The votes were as follows:

 

RESOLUTION

VOTES FOR

%

VOTES AGAINST

%

VOTES WITHHELD*

1

Report and Accounts

219,104,625

80.85

51,908,041

19.15

101,986,122

2

Final dividend

233,018,515

62.48

139,907,211

37.52

73,062

3

Elect J. Heper

264,206,888

92.73

20,714,828

7.27

88,077,072

4

Elect M. Sutherland

233,010,074

81.78

51,908,621

18.22

88,080,093

5

Re-elect P. Butterfield

222,069,893

77.94

62,848,802

22.06

88,080,093

6

Re-elect A. Franklin

264,044,516

92.67

20,874,179

7.33

88,080,093

7

Re-elect R. Jones

201,039,250

70.56

83,879,445

29.44

88,080,093

8

Re-elect J. LeCouilliard

206,081,209

77.31

60,470,644

22.69

106,446,935

9

Re-elect K. Neirynck

253,533,764

88.98

31,387,952

11.02

88,077,072

10

Appoint Auditor

284,909,887

99.99

7,118

0.01

88,081,783

11

Remuneration of Auditor

284,912,231

99.99

4,328

0.01

88,082,229

12

Allot shares - general

179,118, 371

62.87

105,800,885

37.13

88,079,532

13

Allot shares - additional

178,986,132

62.82

105,933,124

37.18

88,079,532

14

Disapply pre-emption rights - general

228,436,470

80.18

56,483,517

19.82

88,078,801

15

Disapply pre-emption rights - additional

228,318,841

80.13

56,601,146

19.87

88,078,801

The Board notes the votes against Resolutions 2, 5, 7, 8, 12 and 13 and will consult with shareholders to understand their views and publish the results of that consultation in due course.

Chris Chrysanthou
Group General Counsel & Company Secretary
25 May 2023

*Each share carries one vote and a 'vote withheld' is not a vote in law and has not been counted in the calculation of the proportion of the votes for and against the resolution. Any proxy appointments which gave discretion to the Chairman have been included in the 'votes for' total.

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com




Buchanan

+ 44 (0)20 7466 5000

Mark Court / Hannah Ratcliff


alliancepharma@buchanan.uk.com




Numis Securities Limited (Nominated Adviser and Corporate Broking)

+ 44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Sher Shah




Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Broking: Patrick Robb


 

About Alliance

 

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

 

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

 

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

 

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSEEFFIEDSELI